Hitting A Moving Target: Teva’s Dethlefs Discusses US Complex Generics
Lack Of Clarity Over FDA Expectations And Mid-Cycle Changes Add To Challenges
Executive Summary
With a number of US complex generic opportunities in Teva’s pipeline, the company’s executive vice president for North America commercial, Sven Dethlefs, talks about the challenges of bringing complex products to market against a backdrop of evolving FDA requirements.
You may also be interested in...
Alvotech Awaits Date With Destiny, With FDA Inspection To Begin On 6 March
As Alvotech reported its first annual financial results, the company spoke of the imminent FDA inspection at its Icelandic manufacturing facility. An earlier inspection has so far put the kibosh on US approval for Alvotech’s proposed Humira (adalimumab) biosimilar.
After US FDA Advisors Unanimously Back First OTC Naloxone Proposal, Meeting On Second Not Needed
“Meeting is no longer needed,” agency states in announcement. The same committees’ unanimous recommendation during a meeting in February on Emergent’s sNDA for OTC sales of 4-mg naloxone nasal spray made a repeat for HRT’s NDA for 3-mg spray unnecessary.
FDA Guides On Generic Product-Specific Meetings, Under GDUFA III Commitment
With GDUFA III now almost at the five-month stage, the FDA has released draft guidance on product-specific guidance (PSG) meetings between FDA and a prospective applicant, as part of commitments set forth under the Generic Drug User Fee Act.